Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels. Gains were largely seen in the healthcare sector and power sector.

Both, the Sensex and Nifty, ended their day at record closing highs. At the closing bell, the BSE Sensex stood higher by 7 points (up 0.02%) and the NSE Nifty closed higher by 19 points (up 0.17%). The BSE Mid Cap index ended the day up by 0.5%, while the BSE Small Cap index ended the day up by 0.3%.

Asian stock markets finished on a positive note as of the most recent closing prices. The Hang Seng stood up by 0.56% and the Nikkei was trading up by 0.09%. The Shanghai Composite stood higher by 1.29%.

European markets were trading on a mixed note. The FTSE 100 was down by 0.23%. The DAX was up by 0.63% while the CAC 40 was up by 0.75%.

The rupee was trading at 69.85 to the US$ at the time of writing.

In the news from pharma space, Lupin share price was in focus today as the company said it has received final approval from the United States Food and Drug Administration (USFDA) to market Hydrocortisone Butyrate lotion.

Hydrocortisone Butyrate Lotion is the generic version of PreCision’s Locoid Lotion, 0.1%. It is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

Owing to the above news, Lupin share price witnessed buying interest and ended the day up by 2.2% on the BSE. As per the data, the lotion had annual sales of approximately US$ 13.8 million in the US.

Speaking of drug approvals, Indian pharma companies catering to the US markets are breathing a sigh of relief. After being adversely affected by import bans and the suspension of new drug approvals from manufacturing facilities in the past three years, there has been a sharp pick-up in new drug approvals in FY17.